trial

Monotherapy of an NMDA Enhancer for Schizophrenia

NCTId NCT04745143
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 80 (estimated)
Sponsored by China Medical University Hospital
Primary completion 2027-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
80 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-01-01
Primary completion
2027-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
NMDAE

Sponsors

China Medical University HospitalLead Sponsor
National Health Research Institutes, TaiwanCollaborator

Sites

1 total
Taichung, Taiwan

Linked catalysts

1
Monotherapy of an NMDA Enhancer for Schizophrenia — primary completion2027-09

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE2
Primary Completion Date
2027-09
Status
RECRUITING
relationships
The graph out of here
drug
NMDAE
drug
lead_sponsor
China Medical University Hospital
company
collaborator
National Health Research Institutes, Taiwan
company
indication
Schizophrenia
indication
Schizophrenia
indication